Delamanid: A new armor in combating drug‑resistant tuberculosis

Xavier, Alphienes Stanley; Lakshmanan, Mageshwaran

doi:10.4103/0976-500X.136121

Molecules of the MillenniumJournal of Pharmacology and PharmacotherapeuticsVol. 5 | Issue 3 | 2014 | pp. 222–224Open access

Delamanid: A new armor in combating drug‑resistant tuberculosis

¹^*,
¹

¹ Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.

Correspondence: Alphienes Stanley Xavier
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.

Published:: Jan 1, 2014
Received:: Jan 20, 2014
Accepted:: Apr 3, 2014
DOI:: 10.4103/0976-500X.136121

How to cite

Xavier, A. S., & Lakshmanan, M. (2014). Delamanid: A new armor in combating drug‑resistant tuberculosis. Journal of Pharmacology and Pharmacotherapeutics, 5(3), 222–224. https://doi.org/10.4103/0976-500X.136121

Abstract

Intense search has been made in the discovery of newer anti‑TB drugs to tackle the issues such as drug resistance, HIV co‑infection and risk of drug‑drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR‑TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug‑drug interactions and better tolerability.

Keywords

Subject

Article metadata

Title	Delamanid: A new armor in combating drug‑resistant tuberculosis
Authors	Alphienes Stanley Xavier; Mageshwaran Lakshmanan
Affiliations	Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
Journal	Journal of Pharmacology and Pharmacotherapeutics
Volume / Issue	Vol. 5, Issue 3 (2014)